280 related articles for article (PubMed ID: 31672301)
1. A Guide to Pheochromocytomas and Paragangliomas.
Guilmette J; Sadow PM
Surg Pathol Clin; 2019 Dec; 12(4):951-965. PubMed ID: 31672301
[TBL] [Abstract][Full Text] [Related]
2. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
Guo Z; Lloyd RV
Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
[TBL] [Abstract][Full Text] [Related]
3. Challenges in Paragangliomas and Pheochromocytomas: from Histology to Molecular Immunohistochemistry.
Juhlin CC
Endocr Pathol; 2021 Jun; 32(2):228-244. PubMed ID: 33768452
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas.
Cassol CA; Winer D; Liu W; Guo M; Ezzat S; Asa SL
Mod Pathol; 2014 Aug; 27(8):1050-62. PubMed ID: 24390213
[TBL] [Abstract][Full Text] [Related]
5. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
[TBL] [Abstract][Full Text] [Related]
6. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations.
Loriot C; Burnichon N; Gadessaud N; Vescovo L; Amar L; Libé R; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2012 Jun; 97(6):E954-62. PubMed ID: 22492777
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical Staining for SOX10 and SDHB in SDH-Deficient Paragangliomas Indicates that Sustentacular Cells Are Not Neoplastic.
Powers JF; Tischler AS
Endocr Pathol; 2020 Sep; 31(3):307-309. PubMed ID: 32562155
[No Abstract] [Full Text] [Related]
8. [Pathologist contribution in the diagnosis of hereditary predisposition to paranganglioma and pheochromocytoma].
Broudin C; Favier J; Verkarre V; Méatchi T
Ann Pathol; 2020 Apr; 40(2):134-141. PubMed ID: 32146049
[TBL] [Abstract][Full Text] [Related]
9. Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma.
Nakamura E; Kaelin WG
Endocr Pathol; 2006; 17(2):97-106. PubMed ID: 17159241
[TBL] [Abstract][Full Text] [Related]
10. Familial pheochromocytomas and paragangliomas.
King KS; Pacak K
Mol Cell Endocrinol; 2014 Apr; 386(1-2):92-100. PubMed ID: 23933153
[TBL] [Abstract][Full Text] [Related]
11. A Previously Unrecognized Monocytic Component of Pheochromocytoma and Paraganglioma.
Farhat NA; Powers JF; Shepard-Barry A; Dahia P; Pacak K; Tischler AS
Endocr Pathol; 2019 Jun; 30(2):90-95. PubMed ID: 31001800
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
13. Morphologic Clues to Succinate Dehydrogenase (SDH) Deficiency in Pheochromocytomas and Paragangliomas.
Turchini J; Gill AJ
Am J Surg Pathol; 2020 Mar; 44(3):422-424. PubMed ID: 31789631
[No Abstract] [Full Text] [Related]
14. SDH-related pheochromocytoma and paraganglioma.
Kantorovich V; King KS; Pacak K
Best Pract Res Clin Endocrinol Metab; 2010 Jun; 24(3):415-24. PubMed ID: 20833333
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation.
Kamai T; Murakami S; Arai K; Nishihara D; Uematsu T; Ishida K; Kijima T
BMC Cancer; 2022 Mar; 22(1):289. PubMed ID: 35300626
[TBL] [Abstract][Full Text] [Related]
16. No child left behind in SDHB testing for paragangliomas and pheochromocytomas.
Schiffman JD
J Clin Oncol; 2011 Nov; 29(31):4070-2. PubMed ID: 21969491
[No Abstract] [Full Text] [Related]
17. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas.
Mete O; Asa SL; Gill AJ; Kimura N; de Krijger RR; Tischler A
Endocr Pathol; 2022 Mar; 33(1):90-114. PubMed ID: 35285002
[TBL] [Abstract][Full Text] [Related]
18. Paraganglioma and pheochromocytoma upon maternal transmission of SDHD mutations.
Bayley JP; Oldenburg RA; Nuk J; Hoekstra AS; van der Meer CA; Korpershoek E; McGillivray B; Corssmit EP; Dinjens WN; de Krijger RR; Devilee P; Jansen JC; Hes FJ
BMC Med Genet; 2014 Oct; 15():111. PubMed ID: 25300370
[TBL] [Abstract][Full Text] [Related]
19. An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma.
Buffet A; Burnichon N; Favier J; Gimenez-Roqueplo AP
Best Pract Res Clin Endocrinol Metab; 2020 Mar; 34(2):101416. PubMed ID: 32295730
[TBL] [Abstract][Full Text] [Related]
20. SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T).
Papathomas TG; Oudijk L; Persu A; Gill AJ; van Nederveen F; Tischler AS; Tissier F; Volante M; Matias-Guiu X; Smid M; Favier J; Rapizzi E; Libe R; Currás-Freixes M; Aydin S; Huynh T; Lichtenauer U; van Berkel A; Canu L; Domingues R; Clifton-Bligh RJ; Bialas M; Vikkula M; Baretton G; Papotti M; Nesi G; Badoual C; Pacak K; Eisenhofer G; Timmers HJ; Beuschlein F; Bertherat J; Mannelli M; Robledo M; Gimenez-Roqueplo AP; Dinjens WN; Korpershoek E; de Krijger RR
Mod Pathol; 2015 Jun; 28(6):807-21. PubMed ID: 25720320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
